ProCE Banner Activity

Contemporary Management of HIV: Emerging ART Paradigms

Slideset Download
Download this expert-authored slideset to review key data on emerging ART strategies, including rapid ART initiation, dual therapy, and long-acting antiretrovirals. (Updated September 2, 2019 with data from IAS 2019)

Released: January 30, 2019

Expiration: January 29, 2020

Share

Faculty

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Program Director Disclosure

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, and ViiV Healthcare.

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, has disclosed that she has received consulting fees from GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, Merck, and Theratechnologies; has received funds for research support from Gilead Sciences, GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, Merck, and Theratechnologies; and has ownership interest in Gilead Sciences, GlaxoSmithKline/ViiV, Janssen/Johnson & Johnson, and Merck.

Faculty Disclosure

Primary Author

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Gilead Sciences and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.